Healthcare | Cambridge, Mass.
Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines
Be Biopharma, developing B cells into medicines, closed a $52 million Series A round led by Atlas Venture and RA Capital Management and joined by Alta Partners, Longwood Fund and Takeda Ventures. Funding will be used to precisely engineer B cells to treat a range of diseases, creating a whole new class of medicine. [Full story]